Clinical CRO

A Contract Research Company that integrates with a Clinical Research Network into part of a healthcare company.

campaign hero banner

Who are we?

GenesisCare Clinical CRO is an independent company founded by GenesisCare, with people skilled across the full spectrum of traditional CRO service offerings yet connected through GenesisCare to additional research services and investigator sites.

Make an enquiry

Get in touch if you would like more information about our CRO services or Clinical Trial Network.

1300 086 870
1300 086 870

What we offer

Why partner with GenesisCare Clinical CRO?

We offer a unique model integrating a Contract Research Organisation with our Clinical Research Network as well as a bespoke model to fit each client’s needs. Our integrated model leads to faster, better designed and cost-effective drug development:

  • direct to site communication and transparency
  • rapid access to information on patient availability (e.g. eMR)
  • better study feasibility & site selection
  • better patient recruitment & retention
  • faster escalation & resolution of issues
  • improved investigator/site engagement
  • key opinion leader input into study design & reporting
  • access to “Real World Data” & patient registries

Single point of contact for the CRO and Clinical Research Network

We are not restricted to the use of GenesisCare sites, however, advantages lies within our integration.

Our point of difference

  1. Integrated model of Clinical Research Network and CRO embedded in a health care company
  2. International, private Clinical Research Network with:
    • state of the art equipment
    • standardised treatment pathways
  3. CRO research capabilities tailored to facilitate research in therapeutic areas of GenesisCare’s specialisation
  4. Advanced information technology platform with eMR and patient reported outcomes capability allowing:
    • extraction of Real World Data
    • construction of registries
    • support for commercialisation
  5. Nuclear Medicine Services:
    • dosimetry
    • central imaging


Australia R&D Tax Incentive

GenesisCare CRO provides full Australian delivery to help leverage the full benefits of the R&D Tax Incentive

Data and Innovation

The CRO leverages GenesisCare's newly established division to accelerate innovation

GenesisCare has established electronic medical records eMRs and applications to allow patient reported outcomes in the therapeutic care pathways for radiation oncology and cardiovascular patients.

In the oncology therapeutic area, physician-led Tumour Reference Groups are standardising the treatment pathways and creating Minimum Data Sets (MDS).

MDS form the basis of data registries used for clinical research.

A hands-on approach

Clinical Services

Empowered project managers and clinical teams to partner together to deliver on timelines and budgets

Medical Services and Safety

Extensive in-house medical expertise and pharmacovigilance services from protocol inception to Clinical Study Report delivery


Data management and biostatistical services involved from protocol build to final output


Strong quality measures put in place from award to ensure appropriate training, review and adherence to regulations

CRO Project Manager coordination of all services for Clients

The CRO Project Manager coordinates all GenesisCare Clinical CRO services for the Client as well as services required from any external vendors, GenesisCare’s  Research Network, GenesisCare’s Nuclear Medicine Services and Central Imaging Services. The Project Manager also coordinates any required non-GenesisCare sites. Independent Quality Assurance oversight is provided by GenesisCare Quality Assurance team.

Clinical Research Network Sites

Stereotactic radiosurgery

Stereotactic radiosurgery, or SRS, is often described as brain-area-sparing surgery. It delivers precisely-focused radiation beams at higher doses in a single or few short treatments and permits the maximum conformal dose delivery within the targets while minimising dose to the surrounding unaffected brain.

Recent studies are showing that treatment with SRS alone results in less decline in cognitive deterioration and better quality of life. Vitally this is achieved with no significant difference in overall survival.¹ SRS is now replacing conventional whole brain radiation therapy as the procedure of choice for some primary tumours and solitary or multiple brain metastases.


Brain metastases

Brain metastases (secondary brain cancer) affect up to 30% of all cancer patients. Lung cancer, breast cancer, kidney cancer and melanoma are the most common primary tumours that metastasise to the brain.

Stereotactic radiosurgery (SRS) has become increasingly recognised world-wide as the as the gold standard radiotherapy option by professional societies, based on a growing evidence base for the use of SRS alone for a patient presenting with one to four brain metastases.2

SRS is routinely used in re-irradiation after brain radiotherapy or previous SRS. 

SRS is also indicated for:  

  • Meningiomas, acoustic neuromas and primary pituitary tumours. 
  • Other non-cancer conditions – eg. arteriovenous malformations, complex trigeminal neuralgia.


  1. Brown et al., 2016; JAMA; 316 (4):401-409. 
  2. Chao T. et al., 2018; Neurosurgery; 83 (3):345-353.

Clinical Research Network: Cancer Care Research

Gamma Knife® Radiosurgery for Intracranial conditions

Gamma Knife Radiosurgery is a highly advanced non-invasive option for both malignant and benign intracranial conditions.

The Gamma Knife is widely recognized by some as the gold standard in radiosurgery due to its long history of use as a radiosurgical modality and the vast amount of literature reporting on clinical efficacy and safety.

Gamma Knife radiosurgery delivers 192 collimated Cobalt- 60 beams to one or more targets in a single session, with submillimetre accuracy.

Fractionated treatment (multi session up to 5 sessions) can also be delivered using a frameless technique.

  • Treatment is non-invasive avoiding complications of surgery (day procedure)
  • Preferential to Whole Brain Radiotherapy (WBRT) for multiple brain metastases of limited number (gamma knife capable of superior low dose wash to normal brain comparable to other radiosurgical modalities)
  • Clear clinical advantages and better outcomes with SRS over surgery for certain indications (for example preservation of serviceable hearing in most patients with an acoustic neuroma).
  • No cessation of systemic treatment and the ability to maintain drug dosing parameters
  • Enables the clinician to plan and treat in a single session, generally done on the same day
  • Fewer side effects than standard conventional radiation therapy, reduced fatigue and no hair loss.
  • Offers the lowest extracranial dose compared to other radiosurgical modalities (children and women of child- bearing age)

Most common indications

  • Brain metastases
  • Meningiomas
  • Vestibular schwannomas
  • Pituitary adenomas
  • Arteriovenous malformations (AVMs)
  • Trigeminal neuralgia

Less common indications

  • Primary malignant brain tumours
  • Movement disorders
  • Epilepsy e.g. hypothalamic hamartomas

SRS vs WBRT: A summary of the evidence

Whole brain radiation therapy (WBRT) was historically the standard treatment for patients with multiple brain metastases but is associated with limited tumour control and cognitive decline. Stereotactic radiosurgery (SRS) permits high dose delivery to targets while minimising dose to surrounding normal brain.

Although WBRT with SRS has been shown to result in less frequent intracranial tumour progression than SRS alone, numerous studies have failed to show a significant difference in overall survival for patients treated with SRS alone. In addition, there Is randomised evidence showing better QoL in patients treated with SRS alone in one to three metastases

The complex brain lesion multidisciplinary team

Macquarie University Hospital and GenesisCare provide a collaborative multidisciplinary approach to care with a team (MDT) comprising of Neurosurgeons, Radiation Oncologists, Medical Physicists, Radiation Therapists and Nurses.

Gamma Knife is not necessary for all patients, so the purpose of the MDT is to discuss and review individual cases to explore all possible treatment options before Gamma Knife treatment is approved.

How to refer

Phone: (02) 9812 3220

Fax: (02) 9812 3389

Rebecca Cox:

Find out more about gamma knife


¹ Brown et al., 2016; JAMA; 316 (4):401-409.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.